219 related articles for article (PubMed ID: 22033636)
1. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
Petrini I; Lencioni M; Ricasoli M; Iannopollo M; Orlandini C; Oliveri F; Bartolozzi C; Ricci S
Cancer Chemother Pharmacol; 2012 Mar; 69(3):773-80. PubMed ID: 22033636
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL
J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Kim JW; Lee JO; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Am J Clin Oncol; 2011 Apr; 34(2):125-9. PubMed ID: 20308869
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Prete SD; Montella L; Caraglia M; Maiorino L; Cennamo G; Montesarchio V; Piai G; Febbraro A; Tarantino L; Capasso E; Palmieri G; Guarrasi R; Bianco M; Mamone R; Savastano C; Pisano A; Vincenzi B; Sabia A; D'Agostino A; Faiola V; Addeo R
Cancer Chemother Pharmacol; 2010 Oct; 66(5):837-44. PubMed ID: 20041325
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in advanced hepatocellular carcinoma.
Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
[TBL] [Abstract][Full Text] [Related]
9. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Song T; Zhang W; Wu Q; Kong D; Ma W
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Hollebecque A; Cattan S; Romano O; Sergent G; Mourad A; Louvet A; Dharancy S; Boleslawski E; Truant S; Pruvot FR; Hebbar M; Ernst O; Mathurin P
Aliment Pharmacol Ther; 2011 Nov; 34(10):1193-201. PubMed ID: 21958438
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
Shacham-Shmueli E; Geva R; Figer A; Bulocinic S; Nalbandyan K; Shpigel S; Atsmon J; Brendel E
J Clin Pharmacol; 2012 May; 52(5):656-69. PubMed ID: 22232731
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Rimassa L; Santoro A
Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
Ikeda M; Okusaka T; Ueno H; Takezako Y; Morizane C
Cancer; 2005 Feb; 103(4):756-62. PubMed ID: 15637692
[TBL] [Abstract][Full Text] [Related]
14. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
Kuroda M; Kobayashi Y; Urawa N; Yamamoto M; Mifuji R; Araki J; Tanaka H; Horiike S; Itani T; Furjita N; Konishi M; Iwasa M; Kaito M; Adachi Y
Hepatogastroenterology; 2007 Mar; 54(74):518-21. PubMed ID: 17523311
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
16. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
17. Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Poggi G; Montagna B; Melchiorre F; Quaretti P; Delmonte A; Riccardi A; Tagliaferri B; Sottotetti F; Di Cesare P; Stella MG; Villani L; Zorzetto M; Greco G; Cornalba G; Bernardo G
Anticancer Res; 2011 Nov; 31(11):3927-33. PubMed ID: 22110221
[TBL] [Abstract][Full Text] [Related]
18. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
Richly H; Schultheis B; Adamietz IA; Kupsch P; Grubert M; Hilger RA; Ludwig M; Brendel E; Christensen O; Strumberg D
Eur J Cancer; 2009 Mar; 45(4):579-87. PubMed ID: 19101137
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
